Atrium Therapeutics, Inc. (RNA)
NasdaqGS
Price as at 1 Oct 2026, 00:42 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Atrium Therapeutics, Inc. trades at $8.28. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Two Sigma, TWO SIGMA INVESTMENTS, LP$4.65M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$2.70M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$2.32M · 0.0% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$1.74M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$909.7K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own RNA?
6 of the institutions we track reported a position in RNA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its RNA data?
Fundamentals for RNA come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:42 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RNA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.